In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dealing with the Deconstructors

Executive Summary

While Big Pharma will continue to orchestrate the processes that move new compounds along the value chain from discovery to market, the value chain itself increasingly transcends company boundaries. A variety of new focused businesses, based on services and technologies, have emerged, differing greatly from the integrated model embraced by today's major players. Big Pharma's critical decisions about when to partner and when to compete with these new entrants will be based not only on the capabilities and market position of the new players but also on the strategies, culture and organization of traditional drug firms.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts